WO2000001724A1 - Proteines de tube polaire de microsporidie, acides nucleiques codant pour ces proteines et leurs applications - Google Patents
Proteines de tube polaire de microsporidie, acides nucleiques codant pour ces proteines et leurs applications Download PDFInfo
- Publication number
- WO2000001724A1 WO2000001724A1 PCT/FR1999/001630 FR9901630W WO0001724A1 WO 2000001724 A1 WO2000001724 A1 WO 2000001724A1 FR 9901630 W FR9901630 W FR 9901630W WO 0001724 A1 WO0001724 A1 WO 0001724A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- sequence
- proteins
- seq
- protein
- represented
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/20—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans from protozoa
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56905—Protozoa
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Definitions
- the subject of the invention is purified complete proteins of microsporidia polar tube (PTPs) as well as the genes encoding these proteins, and their use in the fields of diagnosis.
- PTPs microsporidia polar tube
- E. cun iculi is microsporidia, an obligate intracellular parasite, common in many mammals and involved in various infections in humans - mainly in immunocompromised individuals.
- Two other species of the genus Encephali tozoon ⁇ E. intestinalis and E. hell em) are also involved in various opportunistic infections.
- microsporidia is responsible in patients with AIDS for digestive pathologies, but also for ocular, muscular, hepatic damage, rhinosinusitis and systemic infections (1).
- Serological tests have also shown the significant presence of microsporidia in the munocompetent patients, since reaching 8% of the population (2).
- microsporidia 4 types are responsible for human diseases: En t erocyt oz o on, En cepha lit oz o on, Vi t ta f orma and Tra chipl ei st oph ora.
- En t erocyt oz o on 4 types are responsible for human diseases: En t erocyt oz o on, En cepha lit oz o on, Vi t ta f orma and Tra chipl ei st oph ora.
- the emergence of these parasites in human pathology arouses on the part of researchers a growing interest in the systematic, epidemiological, clinical, diagnostic and therapeutic fields.
- diagnosis is based on PCR tests using oligonucleotides determined from ribosomal DNA sequences, the only sequences known in most microsporidia. Therapy, for its part, is limited to the use of certain molecules such as albendazole or fumagillin. These unicellular e
- the spore an infectious stage, in fact contains an extrusion device consisting of a polar tube inserted at its anterior end in an anchoring disc.
- an extrusion device consisting of a polar tube inserted at its anterior end in an anchoring disc.
- the polar tube is extruded from the microsporidian spore and crosses the plasma membrane d 'a host cell.
- the sporoplasm, expelled through this tube is thus inoculated into the receptor cell.
- This invasive device specific to microsporidia and unique in the living world, therefore arouses interest both from a fundamental point of view but also applied for diagnosis and therapy. To date, no complete sequence of proteins constituting this polar tube has been obtained.
- the polar tube is made up of a single 23 kDa protein in Ameson mi cha el is. More recently, in a parasitic microsporidia of fish, Glugea ameri canus, a differential extraction of proteins in the presence of a reducing agent (DTT) has made it possible to demonstrate that a protein of 43 kDa is constitutive of the polar tube, but only part of the N-terminal sequence of 16 amino acids has been determined (4).
- DTT reducing agent
- the research work which led to the present invention, firstly consisted in producing polyclonal and monoclonal antibodies against the polar tube of E. cuni cul i. He thus obtained 2 polyclonal antibodies (anti-55 kDa and anti-35 kDa) and an antibody monoclonal (anti-55 kDa) reacting specifically with the polar tube in immunofluorescence and electron microscopy (6). After separation of the spore proteins by 2-dimensional electrophoresis and transfer to the PVDF membrane, a protein having an apparent molecular mass close to 55 kDa and an isoelectric point of 5 was recognized by these three types of antibodies.
- the experimental protocol included therein comprises conventional steps well known to those skilled in the art (9), such as the extraction of spore proteins, electrophoresis (SDS-PAGE), the production of polyclonal and monoclonal antibodies, the microsequencing of peptides as well as the determination of degenerate primers and their amplification by PCR.
- steps well known to those skilled in the art 9
- the extraction of spore proteins electrophoresis (SDS-PAGE)
- SDS-PAGE electrophoresis
- the production of polyclonal and monoclonal antibodies the microsequencing of peptides as well as the determination of degenerate primers and their amplification by PCR.
- the subject of the invention is therefore complete proteins purified from microsporidia polar tube and more particularly from 3 microsporidian species of the genus Encephali tozoon: E. cuniculi, E. intestinalis and E. hellem. More particularly, the invention relates to:
- the invention therefore relates to polar tube microsporidia proteins whose amino acid sequence is represented in the sequence list in the appendix under the numbers SEQ ID No: 1, SEQ ID No: 2, SEQ ID No: 3, SEQ ID No: 4 and SEQ ID No: 5, a fragment or a functionally equivalent derivative of these.
- the term “functionally equivalent derivative” is intended to mean proteins whose sequence comprises a modification and / or a deletion and / or an addition of one or more amino acid residues, since this modification and / or deletion and / or addition does not not affect the function of these proteins. Such derivatives can be analyzed by a person skilled in the art according to the techniques:
- the protein of 395 amino acids hereinafter designated PTP55, represented in the sequence list in the appendix under the number SEQ ID No: 1 corresponds to the protein of 55 kDa of E cuniculi. It has a deduced molecular mass of 39,609 Da and 37,230 Da without the signal peptide, which is lower than that of 55,000 observed on polyacrylamide gels.
- This protein is synthesized by
- E. cuniculi as a larger precursor of which the signal sequence of 22 amino acids is removed when targeting to vesicle involved in the forma t ion of the pole tube.
- the sequence of a mature protein of the polar tube of the invention therefore corresponds to the sequence between the amino acids in positions 23 and 395 of
- N-terminal sequencing of the protein showed a sequence identical to that of the Pi peptide, confirming that the peptide of 22 amino acids was cleaved during maturation. It is further observed that PTP55 does not contain tryptophan, phenylalanine, or arginine residues. It has an isoelectric point deduced from 4.7 in agreement with that observed on 2-dimensional polyacrylamide gels which was of the order of 5. The study of these sequences of 395 amino acids and 373 amino acids in the mature protein , shows that it has no significant homology with other proteins already described in the databases.
- a protein homologous to PTP55 has also been identified in the species E. intestinalis. This 371 amino acid protein is represented in the sequence list in the appendix under the number SEQ ID No: 3. The sequence notably shows strong homologies with the N- and C-terminal regions of the PTP55 of E. cuniculi.
- PTP35 The protein of 277 amino acids, hereinafter designated PTP35, represented in the sequence list in the appendix under the number SEQ ID No: 2 corresponds to the protein of 35 kDa of E. cuni ass i. It has a deduced molecular mass of 30,075 Da, therefore lower than that of 35,000 observed on polyacrylamide gels.
- SEQ ID No: 2 The protein of 277 amino acids, hereinafter designated PTP35, represented in the sequence list in the appendix under the number SEQ ID No: 2 corresponds to the protein of 35 kDa of E. cuni ass i. It has a deduced molecular mass of 30,075 Da, therefore lower than that of 35,000 observed on polyacrylamide gels.
- the N-terminal end of PTP35 also exhibits signal peptide characteristics:
- PTP35 from E. cuni cul i would present a signal peptide.
- Potential proteolytic cleavage sites can be predicted between residues 12 and 13, 13 and 14 or 22 and 23. However, such cleavage could only be confirmed by sequencing the N-terminal part of the protein.
- the sequence of a polar tube protein according to the invention is between amino acids 1 and 277 of the sequence given in the annex under the number SEQ ID No: 2.
- PTP35 does not contain tryptophan residues. It has an isoelectric point deduced from 8.6 in agreement with that observed on 2-dimensional polyacrylamide gels which was of the order of 9. The study of this sequence of 277 amino acids shows that it has no significant homology with other proteins already described in databases.
- the inventors also obtained proteins homologous to PTP35 in the 2 other species of the genus Encephali tozoon, E. intestinalis and E. hellem.
- the corresponding sequences are appended under the numbers SEQ ID No: 4 and SEQ ID No: 5.
- the PTP35 of E. intestinalis and E. hellem are made up of 275 and 272 amino acids respectively and have around 80% identity.
- sequence of a PT35 protein of the polar tube of the invention corresponds more particularly to a sequence consisting of or comprising:
- Poly or monoclonal antibodies directed against at least one protein of the invention or a fragment thereof can be prepared by the methods described in the literature.
- Polyclonal antibodies are formed according to conventional techniques by injection of proteins, extracted from the spores of E. cuniculi or produced by transformation of a host, in animals, then recovery of antisera and antibodies from antisera for example by affinity chromatography.
- Monoclonal antibodies can be produced by fusing myeloma cells with spleen cells from animals previously immunized with the proteins of the invention. These antibodies are useful for finding other polar tube proteins in E. cuniculi, E. hellem or E. intestinalis and to study the kinship between polar tube proteins of different species, even different genera. Indeed, the antibodies formed against the polar tube of E. intestinalis or E. hellem giving rise to crossed immunological reactions with the proteins of the polar tube of E. c un i cu l i. But they can also find applications in the diagnostic field.
- the invention therefore also relates to a method for diagnosing infections caused by microsporidia of the genus Encephali tozoon comprising the following steps: a) immobilizing a recombinant protein of microsporidial polar tube according to the invention on an analysis support such as a nitrocellulose sheet or an ELISA plate, b) the non-specific reaction sites are saturated, for example in the presence of 5% skimmed milk, c) the product obtained in step (b) is incubated with the antibodies of the serum of the test subject, so that, if the serum contains antibodies directed against a polar tube protein of microsporidia, these complex with said protein, d) washing the antibodies from the serum which are not complexed in step (c), e) incubating the product of step (d) with secondary anti-human antibodies coupled to a molecule allowing their revelation, such as for example an enzyme such as peroxidase or a fluorochrome, f) washing away anti-human antibodies which are not specifically linked and, g) revealing
- a diagnostic kit for the implementation of such a method consists of: an analysis support on which are immobilized recombinant proteins of microsporidia polar tube,
- the invention also relates to a nucleic acid molecule comprising or consisting of a nucleic sequence coding for a polar tube protein of microsporidia. More particularly, the invention relates to the nucleotide sequences coding for the proteins of PTP55 and PTP35 corresponding respectively to the proteins of 55 and 35 kDa of the microsporidia E. cuniculi, E. intestinalis and E. hellem.
- the invention envisages on a specific basis, a nucleic acid molecule comprising or consisting of a nucleic sequence coding for a polar tube protein of microsporidia whose amino acid sequence is represented in the sequence list in the appendix under the number SEQ ID No: 1, SEQ ID No: 2, SEQ ID No: 3, SEQ ID No: 4 or SEQ ID No: 5, a fragment or a functionally equivalent derivative of this protein.
- a DNA molecule comprising the sequence coding for the protein PTP55 of E. cuniculi is represented in the attached sequence list under the number SEQ ID No: 1 or its complementary sequence. More particularly, such a nucleic acid sequence comprises the sequence between nucleotides 411 and 1532 of SEQ ID No: 1 or its complementary sequence.
- the nucleic sequence of SEQ ID No: 1 is composed of 1830 nucleotides and includes an open reading frame of 1188 base pairs ranging from position 345 (start codon ATG) to position 1532 (stop codon TAG). The region preceding position 345 is likely to include elements useful for the transcription of the PTP55 protein such as a promoter region.
- a DNA molecule comprising the sequence coding for a protein homologous to PTP55 identified in the species E. intestinalis is represented in the sequence list in the appendix under the number SEQ ID No: 3.
- a DNA molecule comprising the sequence coding for the protein PTP35 is represented in the annexed sequence list under the number SEQ ID No: 2 or its complementary sequence. More particularly, such a nucleic acid sequence comprises the sequence between nucleotides 458 and 1291 of SEQ ID No: 2 or its complementary sequence.
- the nucleic acid sequence II of the invention is composed of 1740 nucleotides and comprises a open reading frame of 834 base pairs ranging from position 458 (ATG initiation codon) to position 1291 (TAA stop codon). The region preceding position 458 is likely to include elements useful for the transcription of the PTP35 protein such as a promoter region.
- the invention therefore relates very particularly to nucleic acid molecules whose nucleotide sequences are represented in the sequence list in the appendix under the numbers SEQ ID No: 1, SEQ ID No: 2, SEQ ID No: 3, SEQ ID No : 4 and SEQ ID No: 5 as well as all the nucleotide sequences capable of hybridizing with these.
- the invention of course also relates to the nucleotide sequences derived from SED ID No: 1, SEQ ID No: 2, SEQ ID No: 3, SEQ ID No: 4 and SEQ ID No: 5 for example due to the degeneration of the genetic code, which codes for proteins exhibiting polar tube characteristics of microsporidia.
- the invention also relates to a vector comprising at least one preceding nucleic acid molecule, advantageously associated with suitable control sequences, as well as a process for the production or expression in a cellular host of a polar tube protein. microsporidia of the invention or a fragment thereof.
- the preparation of these vectors as well as the production or the expression in a host of the proteins of the invention can be carried out by the techniques of. molecular biology and genetic engineering well known to those skilled in the art.
- a method for producing a polar tube protein of microsporidia consists:
- a method of expressing a polar tube protein of microsporidia according to the invention consists:
- the cell host used in the above methods can be chosen from prokaryotes or eukaryotes and in particular from bacteria, yeasts, mammalian, plant or insect cells.
- the vector used is chosen according to the host to which it will be transferred; it can be any vector such as a plasmid.
- the invention therefore also relates to cellular hosts and more particularly to transformed bacteria such as E. coli, expressing polar tube microsporidia proteins obtained in accordance with the preceding methods.
- the invention also relates to the nucleic acid probes and oligonucleotides prepared from the nucleic acid molecules of the invention.
- probes are useful for the detection by hybridization of similar sequences in other microsporidia.
- these probes are brought into contact with a biological sample.
- Different hybridization techniques can be implemented such as spot hybridization (Dot-blot) or hybridization on replicas (Southern technique) or other techniques (DNA chips).
- Dot-blot spot hybridization
- Southern technique hybridization on replicas
- DNA chips DNA chips
- the oligonucleotides are useful for PCR experiments, for example to search for genes in other microsporidia or for diagnostic purposes.
- the invention therefore also relates to a method for diagnosing infections caused by microsporidia, comprising the following steps: a) DNA is extracted from microsporidian spores taken from biological samples obtained from urine, stool, or a biopsy , b) the DNA extracted is amplified by any appropriate means such as a PCR using specific oligonucleotides derived from the sequences of the genes coding for the microsporidium polar tube proteins, c) the products d are immobilized amplification on an analysis support, d) the microsporidian origin of the amplification products is determined by hybridization using a labeled nucleotide probe specific for microsporidia. It is possible to carry out step (c) by fixing the amplification products on an analysis support, such as a membrane or an ELISA plate.
- an analysis support such as a membrane or an ELISA plate.
- a diagnostic kit for the implementation of such a process consists of
- the invention also relates to vaccine compositions capable of preventing infections caused by microsporidia of the genus Encephali tozoon comprising, as active principle, a protein of the invention or a fragment thereof in association with a pharmaceutically acceptable vehicle.
- the invention advantageously provides a potential vaccine against infections caused by microsporidia of the genus Encephalitozoon.
- A the trophoretic separation of the spore proteins by SDS-PAGE with on track 1 the fraction soluble in SDS 2%, 2-mercaptoethanol 10%, and on track 2 the residual fraction obtained after incubation in 2-mercaptoethanol 50% for 48 hours.
- FIG. 2 shows the immunoreactivity of the 55 kDa protein.
- Two-dimensional gel electrophoresis was performed using isoelectric focusing in the first dimension and 12% gels in the second dimension.
- the separated proteins were either stained with silver nitrate (A) or transferred to PVDF membranes and incubated with polyclonal antibodies directed against the 55 kDa acid spot (dilution l / 5000 e ) isolated by 2D electrophoresis (B) .
- the molecular weights are indicated in kDa and the isoelectric points numbered from 4 to 8.
- FIG. 4 shows an immunostaining performed on 2-dimensional electrophoresis gels with the monoclonal antibody directed against the polar tube.
- Two-dimensional gel electrophoresis was performed using isoelectric focusing in the first dimension and 12% gels in the second dimension.
- the separated proteins were either stained with silver nitrate (A) or transferred to PVDF membranes and incubated with the monoclonal antibody (dilution 1/5000 e ) (B).
- the spots of 55 and 35 kDa are indicated by arrows.
- Figure 5 illustrates the expression of PTP35 in Escherichia coli.
- Figure 5 shows: • in A, analysis on polyacrylamide gels (SDS-PAGE) of proteins extracted from bacteria transformed with the plasmid construction pQE30-PTP35.
- Lane 1 shows production without induction; lane 2 after induction with IPTG and lane 3 recombinant PTP purified on Ni-NTA resin.
- the molecular weight markers are indicated in kDa.
- E. cuniculi Production of antibodies against the polar tube of E. cuniculi, immunocytochemical analyzes.
- the strain of E. cuniculi used is a mouse isolate. It is maintained on MDCK cell culture. The spores released in the culture supernatant are recovered and stored at 4 ° C in PBS.
- the extraction of spore proteins is carried out by grinding the spores with zirconium beads (0.1 mm in diameter) in a buffer containing 2.5% SDS and 10% 2-mercaptoethanol in the presence of protease inhibitors. After heat denaturation for 10 minutes at 100 ° C, the sporal debris is removed by centrifugation at 18000 g for 5 minutes. The proteins are then separated by SDS-PAGE on 12% polyacrylamide gels.
- the protein samples are dissolved in a buffer based on 9 M urea, 5% 2-mercaptoethanol and 40 mM CHAPS.
- the isoelectric focusing is carried out under the following conditions: 4 hours at 400 V, 30 minutes at 600 V then 30 minutes at 800 V with the combination of ampholines (Pharmacia) 40% pH 3-10, 60% pH 4-6, 5.
- the proteins are separated according to their molecular mass by SDS-PAGE.
- the corresponding gels are stained either with silver or Coomassie blue, or transferred onto a PVDF membrane (Immobilon P, Polylabo) using a semi-dry system.
- Polyclonal antibodies have been produced against different proteins of E. cuniculi separated by electrophoresis. Intraperitoneal injections are performed in BALB / c mice for each protein sample. The 55 kDa protein band has also been used to produce monoclonal antibodies. Thus, 3 antibodies directed against the polar tube were obtained: 2 polyclonal anti-35 kDa and anti-55 kDa antibodies and a monoclonal anti-55 kDa antibody. Immunoblotting, immunolocation in IFA and in transmission electron microscopy are carried out according to conventional techniques.
- N-terminal sequence as well as 2 internal peptides (PI and P2) were sequenced for the PTP55 of E. cuniculi.
- ATALCSNAYG PI ATALCSNAYGLTPGQQGMAQ
- P2 SATQYAMEACATPTP
- P3 An internal peptide (P3) has been sequenced for PTP35.
- P3 AVQGTDRCILAGIID These sequences were produced from 55 kDa and 35 kDa proteins isolated by 2-dimensional electrophoresis, by the protein microsequencing laboratory, Institut Pasteur, Department of biotechnology. For the internal sequencing of the peptides PI, P2 and P3, the proteins were previously digested with Endolysin C, a proteolytic enzyme which cuts after a lysine residue.
- the complete sequence represented in the sequence list in the appendix under the number SEQ ID No: 1 comprises 1830 nucleotides and comprises a reading frame of 1188 bp.
- the latter contains 395 codons ranging from the site considered to be the site of initiation of translation to the TAG termination codon.
- the codon considered as starting ATG codon is preceded by a region particularly rich in A-T.
- the translated amino acid sequence is shown in the sequence list in the appendix under the number SEQ ID No: 1.
- the gene coding for a protein homologous to PTP55 has been sequenced and is represented in the sequence list in the appendix under the number SEQ ID No: 3. This sequence includes a reading frame of 1113 bp. The latter contains 371 codons ranging from the site considered to be the site of initiation of translation to the TAG termination codon.
- the complete PTP35 sequence of E. cuniculi represented in the sequence list in the appendix under the number SEQ ID No: 2 comprises 1740 nucleotides.
- the reading frame includes 834pb.
- the latter contains 277 codons ranging from the site considered to be the site of translation initiation to the TAA termination codon.
- the codon considered as starting ATG codon is preceded by a region particularly rich in A-T, similar to that of PTP55.
- the translated amino acid sequence is represented in the attached sequence list under the number SEQ ID No: 2.
- the PTP35 sequences of E. intestinalis and E. hel l em represented in the sequence list in the appendix under the numbers SEQ ID No: 4 and SEQ ID No: 5 contain 825 and 816 nucleotides respectively, not including the stop codon.
- the corresponding proteins consist of 277 and 272 amino acids.
- Part of the PTP35 between residues 27 and 277 was also expressed in E. col i using the same technique.
- the antibodies produced against this recombinant protein showed labeling of the polar tube.
- cun i cul i) is predicted as such by the following characteristics: - absence of lysine residue in position 22 preceding the peptide PI sequence (23-42 ) after digestion of the protein with Endolysin C, N-terminal sequencing of the protein corresponding to that of the PI peptide, - presence of hydrophobic amino acids in this N-terminal region,
- PTP is probably synthesized by E. cuniculi (or E. in tes tinalis) in the form of a larger precursor whose signal sequence of 22 amino acids is eliminated during maturation.
- the mature protein would therefore have a molecular mass of 37,230 Da.
- N-glycosylation sites NETS, NGTS and
- NISG NISG
- the central region of the PTP55 protein of E. cuniculi is characterized by 4 tandem repeats of 26 amino acids each with conservation at the nucleic level. This region is partially surrounded by 2 other repeats of 9 amino acids. No repetition is observed in the PTP55 sequence of E. intestinalis, but the 2 PTP55s show strong homologies in the N- and C-terminal parts.
- PTP35 are particularly rich in lysine (11.5%) and glutamic acid (9%) residues.
- 3 potential cleavage sites of a signal sequence are represented between residues 12 and 13, 13 and 14, and 22 and 23.
- An RGD sequence is present in the PTP35 of E. cuniculi and E. in tes tinal i s, a sequence found in proteins such as fibronectin and which intervenes in cell attachment phenomena.
- a potential N-glycosylation site (NSTS) is also present in the PTP35 sequence of E. cuniculi.
- the same probe was applied to Southern after digestion of the genomic DNA of E. cuni cul i by different restriction enzymes: a single band is marked on each digestion profile, which confirms that the gene exists in a single copy.
- the gene encoding E. cuni cul i is also located on chromosome VI.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Cell Biology (AREA)
- Zoology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Virology (AREA)
- Food Science & Technology (AREA)
- Veterinary Medicine (AREA)
- Biotechnology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002333919A CA2333919A1 (fr) | 1998-07-07 | 1999-07-06 | Proteines de tube polaire de microsporidie, acides nucleiques codant pour ces proteines et leurs applications |
AU46240/99A AU4624099A (en) | 1998-07-07 | 1999-07-06 | Microsporidium polar tube proteins, nucleic acids coding for said proteins and their uses |
EP99929415A EP1093461A1 (fr) | 1998-07-07 | 1999-07-06 | Proteines de tube polaire de microsporidie, acides nucleiques codant pour ces proteines et leurs applications |
US09/755,456 US6890536B2 (en) | 1998-07-07 | 2001-01-05 | Microsporidian polar tube proteins, nucleic acids coding for these proteins and their applications |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR98/08692 | 1998-07-07 | ||
FR9808692A FR2780978B1 (fr) | 1998-07-07 | 1998-07-07 | Proteines de tube polaire de microsporidie, acides nucleiques codant pour ces proteines et leurs applications |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/755,456 Continuation US6890536B2 (en) | 1998-07-07 | 2001-01-05 | Microsporidian polar tube proteins, nucleic acids coding for these proteins and their applications |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2000001724A1 true WO2000001724A1 (fr) | 2000-01-13 |
Family
ID=9528366
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/FR1999/001630 WO2000001724A1 (fr) | 1998-07-07 | 1999-07-06 | Proteines de tube polaire de microsporidie, acides nucleiques codant pour ces proteines et leurs applications |
Country Status (6)
Country | Link |
---|---|
US (1) | US6890536B2 (fr) |
EP (1) | EP1093461A1 (fr) |
AU (1) | AU4624099A (fr) |
CA (1) | CA2333919A1 (fr) |
FR (1) | FR2780978B1 (fr) |
WO (1) | WO2000001724A1 (fr) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN116925198B (zh) * | 2023-08-15 | 2024-05-14 | 西南大学 | 一种微孢子虫极管蛋白EcPTP1的重组蛋白及其制备方法和应用 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998002745A1 (fr) * | 1996-07-11 | 1998-01-22 | Heinz Rinder | Detection de microsporidies et microsporidioses |
-
1998
- 1998-07-07 FR FR9808692A patent/FR2780978B1/fr not_active Expired - Fee Related
-
1999
- 1999-07-06 EP EP99929415A patent/EP1093461A1/fr not_active Withdrawn
- 1999-07-06 AU AU46240/99A patent/AU4624099A/en not_active Abandoned
- 1999-07-06 WO PCT/FR1999/001630 patent/WO2000001724A1/fr not_active Application Discontinuation
- 1999-07-06 CA CA002333919A patent/CA2333919A1/fr not_active Abandoned
-
2001
- 2001-01-05 US US09/755,456 patent/US6890536B2/en not_active Expired - Fee Related
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998002745A1 (fr) * | 1996-07-11 | 1998-01-22 | Heinz Rinder | Detection de microsporidies et microsporidioses |
Non-Patent Citations (10)
Title |
---|
BIDERRE C ET AL: "Mapping of repetitive and non-repetitive DNA probes to chromosomes of the microsporidian Encephalitozoon cuniculi", GENE: AN INTERNATIONAL JOURNAL ON GENES AND GENOMES, vol. 191, no. 1, 20 May 1997 (1997-05-20), pages 39-45, XP004074957 * |
E.M. KEOHANE ET AL.,: "Identification of a microsporidian polar tube protein reactive monoclonal antibody", THE JOURNAL OF EUKARYOTIC MICROBIOLOGY, vol. 43, no. 1, 1996, pages 26 - 31, XP002098789 * |
E.M. KEOHANE ET AL.,: "THE MOLECULAR CHARCTERIZATION OF THE MAJOR POLAR TUBE PROTEIN GENE FROM ENCEPHALITOZOON HELLEM, A MICROSPORIDIAN PARASITE OF HUMANS", MOLECULAR AND BIOCHEMICAL PARASITOLOGY, vol. 94, August 1998 (1998-08-01), pages 227 - 236, XP002098791 * |
F. DELBAC ET AL.,: "First complete amino acid sequence of a polar tube protein in microsporidian species, Encephalitozoon cunuculi", THE JOURNAL OF EUKARYOTIC MICROBIOLOGY, vol. 44, no. 6, 1997, pages 77S, XP002098786 * |
F. DELBAC ET AL.,: "Identification of sporal proteins in two microsporidian species: an immunoblotting and immunocytochemical study", THE JOURNAL OF EUKARYOTIC MICROBIOLOGY, vol. 43, no. 5, 1996, pages 101S, XP002098788 * |
F. DELBAC ET AL.,: "Immunocytochemical identification of spore proteins in two microsporidia, with emphasis on extrusion apparatus", JOURNAL OF EUKARYOTIC MICROBIOLOGY, vol. 45, no. 2, April 1998 (1998-04-01), pages 224 - 231, XP002098787 * |
F. DELBAC ET AL.,: "On proteins on the microsporidian invasive apparatus: complete sequence of a polar tube protein of Encephalitozoon cuniculi", MOLECULAR MICROBIOLOGY, vol. 29, no. 3, August 1998 (1998-08-01), pages 825 - 834, XP002098792 * |
H.D. LUJAN ET AL.,: "Detection of microsporidia spore-specific antigens by monoclonal antibodies", HYBRIDOMA, vol. 17, no. 3, June 1998 (1998-06-01), pages 237 - 243, XP002098790 * |
KATZWINKER-WLADARSCH S ET AL: "DIRECT AMPLIFICATION AND SPECIES DETERMINATION OF MICROSPORIDIAN DNA FROM STOOL SPECIMENS", TROPICAL MEDICINE AND INTERNATIONAL HEALTH, vol. 1, no. 3, 1 June 1996 (1996-06-01), pages 373 - 378, XP002044635 * |
WEISS L M ET AL: "UTILITY OF MICROSPORIDIAN RRNA IN DIAGNOSIS AND PHYLOGENY: A REVIEW", FOLIA PARASITOLOGICA, vol. 41, 1994, pages 81 - 90, XP002044634 * |
Also Published As
Publication number | Publication date |
---|---|
US20010021512A1 (en) | 2001-09-13 |
CA2333919A1 (fr) | 2000-01-13 |
AU4624099A (en) | 2000-01-24 |
EP1093461A1 (fr) | 2001-04-25 |
US6890536B2 (en) | 2005-05-10 |
FR2780978B1 (fr) | 2003-04-11 |
FR2780978A1 (fr) | 2000-01-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Reina-San-Martin et al. | A B-cell mitogen from a pathogenic trypanosome is a eukaryotic proline racemase | |
EP0423301B1 (fr) | Peptides synthetiques du conjugue de l'ubiquitine et de l'histone h2a | |
EP0528932B1 (fr) | Proteine associee a la pancreatite aigue, moyens pour le diagnostic de la pancreatite aigue | |
EP0648269A1 (fr) | Nouveaux polypeptides ayant une activite de recepteur nmda, acides nucleiques codant pour ces polypeptides et utilisations | |
Günsel et al. | In vivo dissection of the intrinsically disordered receptor domain of Tim23 | |
FR2705358A1 (fr) | Procédé de culture in vitro de différents stades de parasites tissulaires, stades parasitaires obtenus et applications biologiques. | |
WO2000001724A1 (fr) | Proteines de tube polaire de microsporidie, acides nucleiques codant pour ces proteines et leurs applications | |
FR2664613A1 (fr) | Sequence peptidique immunogene d'echinococcus granulosus, sequence d'adn codant pour cette sequence peptidique et applications diagnostiques et therapeutiques. | |
EP0407230B1 (fr) | Protéine antigénique du stade sporozoite et hépatique de P. falciparum | |
WO2006027431A1 (fr) | Nouvelles proteines permettant, notamment, la mise en evidence in vitro et la prevention des infections a legionella pneumophila | |
EP1804061A1 (fr) | Utilisation de la protéine 5E2 dans le diagnostic in vitro d'infections à Legionella pneumophila | |
FR2665365A1 (fr) | Antigene de plasmodium falciparum susceptible d'induire des anticorps protecteurs - application a la vaccination. | |
FR2834294A1 (fr) | Virus hxhv, materiel nucleique, materiel peptidique et utilisations | |
EP1539963A2 (fr) | Proteine recombinante chimerique et diagnostic in vitro du hiv | |
FR2615104A1 (fr) | Nouvelle protease de plasmodium falciparum, anticorps diriges contre cette protease, substrats peptidiques specifiques de ladite protease, et leur utilisation comme medicament contre le paludisme | |
EP0253698B1 (fr) | Procédé d'analyse de séquences peptidiques immunogènes en vue de la production de vaccins | |
FR2748812A1 (fr) | Trousse de diagnostic et procede pour determiner la concentration d'un cytochrome p450 | |
WO2009138689A2 (fr) | Détection, in vitro, d'anticorps produits à la suite d'une infection à legionella pneumophila | |
EP2041179A2 (fr) | Structure antigenique de surface de cellules spermatiques associee au chromosome y | |
FR2821085A1 (fr) | Nouvelles metalloproteases possedant des domaines thrombospondine et compositions d'acides nucleiques les codant | |
FR2878861A1 (fr) | Nouvelles proteines permettant la mise en evidence in vitro et la prevention des infections a legionella pneumophila | |
WO1998034637A1 (fr) | Utilisation d'un polypeptide, pour obtenir une composition pour detecter, prevenir ou traiter une maladie degenerative et/ou auto-immune | |
FR2872289A1 (fr) | Utilisation de la proteine g5 dans le diagnostic in vitro d'infection a legionella pneumophila | |
FR2614305A2 (fr) | Proteine p28ii utile notamment dans la prevention de la schistosomose et son procede de preparation. | |
WO1991013987A2 (fr) | Adnc codante pour le gene n du virus de la septicemie hemorragique virale et ses utilisations |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
ENP | Entry into the national phase |
Ref document number: 2333919 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1999929415 Country of ref document: EP Ref document number: 09755456 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 1999929415 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1999929415 Country of ref document: EP |